Changeflow GovPing Pharma & Drug Safety Fused Benzoisoxazolyl Compounds as KAT6A Inhibi...
Routine Rule Added Final

Fused Benzoisoxazolyl Compounds as KAT6A Inhibitors

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4448109A1 for fused benzoisoxazolyl compounds as KAT6A inhibitors, filed jointly by Aurigene Oncology Limited and Olema Pharmaceuticals, Inc. The invention covers heterocyclic antineoplastic compounds classified under A61P 35/00 and C07D 498/04. The patent is designated for all European Patent Convention contracting states.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The European Patent Office published patent application EP4448109A1, filed by Aurigene Oncology Limited and Olema Pharmaceuticals, Inc., covering fused benzoisoxazolyl compounds as KAT6A inhibitors for antineoplastic applications. The compounds are classified under IPC categories A61P 35/00, A61P 35/02, C07D 498/04, and A61K 31/42.

Competitors developing KAT6A-targeted oncology therapies should review the patent claims for potential freedom-to-operate concerns. The patent designation across all EPC contracting states means protection extends across the major European pharmaceutical markets including Germany, France, the United Kingdom, and other EU member states.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS

Publication EP4448109A1 Kind: A1 Apr 08, 2026

Applicants

Aurigene Oncology Limited, Olema Pharmaceuticals, Inc.

Inventors

VENKATESHAPPA, Chandregowda, BERA, Kalisankar, ABBINENI, Chandrasekhar, SAMAJDAR, Susanta, MYLES, David C., HEARN, Brian R.

IPC Classifications

A61P 35/00 20060101AFI20230624BHEP A61P 35/02 20060101ALI20230624BHEP C07D 498/04 20060101ALI20230624BHEP A61K 31/42 20060101ALI20230624BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4448109A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing Drug development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!